Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

infections other than COVID-19 meta-analysis

INSIGHT FLU-IVIG (Davey), 2019
 
NCT02287467
RCTconvalescent plasma treatmentplaceboinfections other than COVID-19some concern
-/- inconclusive
IRC005 Study Team, 2019
 
NCT02572817
RCTconvalescent plasma treatmentplaceboinfections other than COVID-19low
92/48 inconclusive
IRC002 Study Team, 2017
 
NCT01052480
RCTconvalescent plasma treatmentcontrolinfections other than COVID-19some concern
42/45 inconclusive
Hung, 2013
 
NCT01617317
RCTconvalescent plasma treatmentplaceboinfections other than COVID-19some concern
17/18 inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).